Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 4CNS 4Sarcoma 3Lymphoid 2Genitourinary 2Gastrointestinal 2Endocrine 2Dermatologic 2Breast 2Thoracic 1NET 1Myeloid 1

Conditions

Neuroendocrine Tumors 26Sarcoma 4Carcinoma, Neuroendocrine 4Prostatic Neoplasms 3Pheochromocytoma 3Paraganglioma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Breast Neoplasms 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Meningioma 2Melanoma 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Digestive System Neoplasms 2Colonic Neoplasms 2Colonic Diseases 2Carcinoma, Renal Cell 2Carcinoid Tumor 2Adenocarcinoma 2

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endocrine Gland Neoplasms × NET × 30 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡